Development and Validation of an Endometrial Cancer Algorithm in US Claims Data
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70306 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Kimberly Daniels und 12 weiteren Autor:innen. Beteiligte Einrichtung: Carelon Research, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Algorithms, Estrogen Replacement Therapy. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Purpose
This study developed and validated algorithms to identify the incidence of endometrial cancer using ICD‐9‐CM and ICD‐10‐CM coding systems as part of a post‐authorization safety study (EU PAS: EUPAS45602) of vaginal estrogen, estrogen and progestin combination hormone therapy, and non‐users of vaginal estrogen.
Methods
Using national claims data in the HealthCare Integrated Research Database, provisional endometrial cancer cases were identified using a screening algorithm comprising at least one endometrial cancer diagnosis code at any location and position between January 1, 2007 and December 31, 2021. One medical record per case was obtained for 700 provisional cases. Two experts in obstetrics and gynecology adjudicated the medical records classifying each patient as a confirmed case, confirmed non‐case, or unknown. Positive predictive value (PPV), conditional sensitivity assuming all cases were identified by the screening algorithm, and their respective 95% confidence intervals (CI) were calculated. Algorithms were generated by choosing the codes and number of encounters to balance endometrial cancer detection and false positives. Algorithms were trained in a sample of non‐users of vaginal estrogen and tested across treatment groups.
Results
Among the non‐user training set, two visits with ICD‐9‐CM code 182.0 or 182.8 had a PPV of 91.2% (85.4%–95.2%) and sensitivity of 99.3% (95.9%–100.0%). Two visits on separate days with ICD‐10‐CM code C54.1, C54.8, or C54.9 had a PPV of 97.0% (93.6%–98.9%) and sensitivity of 99.5% (97.2%–100.0%). PPVs and sensitivities were over 75% across testing set cohorts for both algorithms.
Conclusion
Two visits with an endometrial cancer diagnosis code accurately identified endometrial cancer cases in both coding systems. There were very few false positive endometrial cancer diagnoses. PPVs and sensitivities were high and similar in all cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Carelon Research, Wilmington, Delaware, USA.
- Pfizer Inc, New York, New York, USA.
- New York University Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Kimberly Daniels, Lauren Parlett
Förderung
- Pfizer
Zitieren
APA
Daniels, K., Wenziger, C., Gandhi, S., Schott, K., Wang, L., Coley, B., Goldstein, S., Parlett, L., Shanmugasandaram, S., Wolter, K., Dai, F., Azarmina, P., & Lanes, S. (2026). Development and Validation of an Endometrial Cancer Algorithm in US Claims Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70306
Vancouver
Daniels K, Wenziger C, Gandhi S, Schott K, Wang L, Coley B, et al. Development and Validation of an Endometrial Cancer Algorithm in US Claims Data. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70306
BibTeX
@article{Daniels2026,
author = {Daniels, Kimberly and Wenziger, Cachet and Gandhi, Sampada and Schott, Kevin and Wang, Li and Coley, Bahar and Goldstein, Steven and Parlett, Lauren and Shanmugasandaram, Saravanan and Wolter, Kevin and Dai, Feng and Azarmina, Pejman and Lanes, Stephan},
title = {Development and Validation of an Endometrial Cancer Algorithm in US Claims Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70306}
}
EUVIMED